Kensei Hashizume

Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation

Takahiko Tanigawa, Masato Kaneko, Kensei Hashizume et al. · Drug Metabolism and Pharmacokinetics · 2012 · 106 citations

Medicine, Cardiology, Pharmacology +15

Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients

Masato Kaneko, Takahiko Tanigawa, Kensei Hashizume et al. · Drug Metabolism and Pharmacokinetics · 2013 · 59 citations

Medicine, Cardiology, Pharmacology +16

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Yu Sunakawa, Junji Furuse, Takuji Okusaka et al. · Investigational New Drugs · 2013 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono et al. · Cancer Chemotherapy and Pharmacology · 2017 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer

Yasuhide Yamada, Naomi Kiyota, Nozomu Fuse et al. · Gastric Cancer · 2013 · 21 citations · Full text

Medicine, Oncology, Pharmacology +12